The monitoring of patients with diabetes has continually evolved with changing technologies. Continuous glucose monitoring (CGM) is becoming an increasingly accessible option for patients to improve glycemic control. Ambulatory glucose profiles, time-in-range and glycemic variability are new measures that can enhance control above a patient’s A1C measurement.
This program is developed in collaboration with Partners in Progressive Medical Education (PPME), and endorsed by Diabetes Canada.
This program has received an educational grant or in-kind support from Abbott Diabetes Care, Astra Zeneca, Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc., Janssen, Novo Nordisk and Sanofi.